Company

NephroGenex, Inc.

NephroGenex develops therapies for kidney diseases, particularly diabetic nephropathy.

About

NephroGenex develops therapies for kidney diseases, with a focus on diabetic nephropathy. Its lead product, PYRIDORIN® (pyridoxamine dihydrochloride), is being evaluated in the Phase 3 PIONEER study. The company is based in the US and went public in February 2014, raising USD 37 mn by issuing 3.1 million shares at an exit share price of USD 12. Wesley Fox is CEO.

5Funding rounds

4Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in